The effect of demographic and clinical factors on the relationship between BMI and PSA levels

Prostate

Volumn 71, Issue 15, 2011, Pages 1631-1637

  Wright, Jonathan L ^a,b   Lin, Daniel W ^a,b   Stanford, Janet L ^b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

body mass index; NSAID; population based; PSA; statin

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTHROPOLOGY; ARTICLE; BODY MASS; DEMOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DEMOGRAPHY; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; OBESITY; PROSTATE-SPECIFIC ANTIGEN;

EID: 80053210058     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21380     Document Type: Article

References (41)

1. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM,. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270 (7): 860-864. (Pubitemid 23234116)
2. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC, Jr., Kane CJ, Amling CL, Moul JW, Freedland SJ,. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298 (19): 2275-2280. (Pubitemid 350146217)
3. Grubb RL, III, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, Riley TL, Ragard LR, Prorok PC, Berg CD, Crawford ED, Church TR, Andriole GL, Jr., Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2009; 18 (3): 748-751.
4. Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ,. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology 2008; 71 (5): 787-791.
5. Rundle A, Neugut AI,. Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate 2008; 68 (4): 373-380. (Pubitemid 351342643)
6. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, Higgins B, Lynch S, Rozanski T, Troyer D, Thompson I,. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005; 103 (5): 1092-1095. (Pubitemid 40270087)
7. Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR, Wener M,. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 2007; 16 (1): 70-76. (Pubitemid 46174266)
8. Culp S, Porter M,. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. BJU Int 2009; 104 (10): 1457-1461.
9. Hekal IA, Ibrahiem EI,. Obesity-PSA relationship: A new formula. Prostate Cancer Prostatic Dis 2009.
10. Loeb S, Carter HB, Schaeffer EM, Ferrucci L, Kettermann A, Metter EJ,. Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol 2009; 182 (6): 2646-2651.
11. Fukui M, Tanaka M, Kadono M, Imai S, Hasegawa G, Yoshikawa T, Nakamura N,. Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care 2008; 31 (5): 930-931.
12. Muller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H,. Association of diabetes and body mass index with levels of prostate-specific antigen: Implications for correction of prostate-specific antigen cutoff values ? Cancer Epidemiol Biomarkers Prev 2009; 18 (5): 1350-1356.
13. Werny DM, Saraiya M, Gregg EW,. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol 2006; 164 (10): 978-983. (Pubitemid 44729839)
14. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC,. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267 (16): 2215-2220.
15. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL,. Statin use and risk of prostate cancer: Results from a population-based epidemiologic study. Am J Epidemiol 2008; 168 (3): 250-260. (Pubitemid 352019786)
16. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D,. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: A preliminary report. J Urol 2005; 173 (6): 1923-1925. (Pubitemid 40675212)
17. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E,. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98 (24): 1819-1825. (Pubitemid 46017933)
18. Chang SL, Harshman LC, Presti JC, Jr., Impact of common medications on serum total prostate-specific antigen levels: Analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 2010; 28 (25): 3951-3957.
19. Fowke JH, Motley SS, Smith JA, Jr., Cookson MS, Concepcion R, Chang SS, Byerly S,. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol 2009; 181 (5): 2064-2070.
20. Singer EA, Palapattu GS, van Wijngaarden E,. Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: Results from the 2001-2002 National Health and Nutrition Examination Survey. Cancer 2008; 113 (8): 2053-2057.
21. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB,. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005; 14 (2): 390-396. (Pubitemid 40270102)
22. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW,. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335 (5): 304-310. (Pubitemid 26362377)
23. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM,. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006; 106 (2): 320-328. (Pubitemid 43100440)
24. Hutterer G, Perrotte P, Gallina A, Walz J, Jeldres C, Traumann M, Suardi N, Saad F, Benard F, Valiquette L, McCormack M, Graefen M, Montorsi F, Karakiewicz PI,. Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. Eur J Cancer 2007; 43 (7): 1180-1187. (Pubitemid 46590732)
25. Ku JH, Kim ME, Lee NK, Park YH, Ahn JO,. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 2003; 61 (1): 132-136. (Pubitemid 36151728)
26. Capitanio U, Perrotte P, Hutterer GC, Suardi N, Jeldres C, Shariat SF, Duclos A, Arjane P, Montorsi F, Karakiewicz PI,. Effect of body mass index on prostate-specific antigen and percentage free prostate-specific antigen: Results from a prostate cancer screening cohort of 1490 men. Int J Urol 2009; 16 (1): 91-95.
27. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE,. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007; 16 (11): 2213-2217. (Pubitemid 351196351)
28. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ,. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008; 100 (21): 1511-1518.
29. Solomon KR, Freeman MR,. Do the cholesterol-lowering properties of statins affect cancer risk ? Trends Endocrinol Metab 2008; 19 (4): 113-121. (Pubitemid 351608305)
30. Hoque A, Chen H, Xu XC,. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2008; 17 (1): 88-94. (Pubitemid 351196277)
31. Murtola TJ, Pennanen P, Syvala H, Blauer M, Ylikomi T, Tammela TL,. Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. Prostate 2009; 69 (9): 1017-1023.
32. Fowke JH, Motley SS, Barocas DA, Cookson MS, Concepcion R, Byerly S, Smith JA, Jr., The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control 2011; 22 (3): 417-426.
33. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ,. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002; 77 (3): 219-225. (Pubitemid 34177596)
34. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ,. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005; 97 (13): 975-980. (Pubitemid 41430563)
35. Stock D, Groome PA, Siemens DR,., Inflammation and prostate cancer: A future target for prevention and therapy ? Urol Clin North Am 2008; 35 (1): 117-130, vii. (Pubitemid 350176596)
36. Wang W, Bergh A, Damber JE,. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005; 11 (9): 3250-3256. (Pubitemid 40627872)
37. Yoo J, Lee YJ,. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Mol Pharmacol 2007; 72 (6): 1586-1592. (Pubitemid 350146095)
38. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM,. The prevalence of prostatism: A population-based survey of urinary symptoms. J Urol 1993; 150 (1): 85-89. (Pubitemid 23175978)
39. Trueman P, Hood SC, Nayak US, Mrazek MF,. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999; 83 (4): 410-415. (Pubitemid 29151164)
40. Norman RW, Nickel JC, Fish D, Pickett SN,. 'Prostate-related symptoms' in Canadian men 50 years of age or older: Prevalence and relationships among symptoms. Br J Urol 1994; 74 (5): 542-550. (Pubitemid 24348617)
41. McAdams MA, Van Dam RM, Hu FB,. Comparison of self-reported and measured BMI as correlates of disease markers in US adults. Obesity (Silver Spring) 2007; 15 1 188-196. (Pubitemid 46219799)